A global pivotal study in participants with KRASG12C mutant locally advanced or metastatic NSCLC comparing first-line treatment of LY3537982 and Pembrolizumab vs. placebo and Pembrolizumab in those with PDL1 expression ≥ 50% and LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs. placebo and Pembrolizumab, Pemetrexed, and Platinum regardless of PD-L1 expression